NEW YORK (GenomeWeb News) – Sigma Life Science has reached a deal to license its CompoZr Zinc Finger Nuclease technology to Horizon Discovery on a non-exclusive basis, Sigma-Aldrich announced today.

Under the terms of the deal, Horizon will use the technology for the commercial development of cell-based products and to provide commercial gene editing services. Additional terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.